Mouth Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major mouth neoplasms markets reached a value of US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.0 Billion by 2034, exhibiting a growth rate (CAGR) of 3.69% during 2024-2034.
The mouth neoplasms market has been comprehensively analyzed in IMARC's new report titled "Mouth Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mouth neoplasms, also known as oral neoplasms or oral tumors, refer to abnormal growths or tumors that develop in the oral cavity. These tumors can occur in various structures within the mouth, including the tongue, lips, cheeks, gums, floor of the mouth, and roof of the mouth (palate). Some of the common symptoms are persistent mouth ulcers that do not heal, lumps or growths in the mouth, pain or discomfort in the throat, difficulty swallowing or chewing, bad breath, loose teeth or changes in dental alignment, unexplained bleeding or numbness in the mouth, etc. The diagnosis of mouth neoplasms involves a comprehensive evaluation by a healthcare professional specializing in oral health and oral pathology. The diagnostic process typically begins with a thorough medical history review and physical examination, including an analysis of the oral cavity and adjacent structures. Various imaging tests, such as X-rays, CT scans, MRI scans, etc., may be conducted to assess the extent and location of the neoplasm. Numerous additional procedures, including blood tests and molecular profiling, are also recommended to provide further information about the tumor's characteristics.
The increasing cases of tobacco use and alcohol consumption, which can damage the cells lining the oral cavity, thereby leading to the development of cancerous tumors, are primarily driving the mouth neoplasms market. In addition to this, the rising prevalence of various associated risk factors, including poor oral hygiene, nutritional deficiencies, excessive exposure to sunlight, inherited genetic syndromes, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of external beam radiation therapy on account of its several benefits, such as targeted treatment, combination therapy potential with surgery or chemotherapy, improved local control, pain management, etc., is further bolstering the market growth. Apart from this, the inflating application of transoral robotic surgery (TORS), since it avoids external incisions, thereby resulting in reduced trauma, minimal scarring, and potentially faster recovery times, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced imaging techniques, such as cone-beam computed tomography, which allows for real-time modifications to the radiation treatment plan, ensuring precise delivery of radiation to the tumor while minimizing exposure to healthy tissues, is expected to drive the mouth neoplasms market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the mouth neoplasms market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mouth neoplasms and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mouth neoplasms market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mouth neoplasms market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mouth neoplasms market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current mouth neoplasms marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the mouth neoplasms market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the mouth neoplasms market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the mouth neoplasms market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of mouth neoplasms across the seven major markets?
What is the number of prevalent cases (2018-2034) of mouth neoplasms by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of mouth neoplasms by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with mouth neoplasms across the seven major markets?
What is the size of the mouth neoplasms patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of mouth neoplasms?
What will be the growth rate of patients across the seven major markets?
Mouth Neoplasms: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for mouth neoplasms drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mouth neoplasms market?
What are the key regulatory events related to the mouth neoplasms market?
What is the structure of clinical trial landscape by status related to the mouth neoplasms market?
What is the structure of clinical trial landscape by phase related to the mouth neoplasms market?
What is the structure of clinical trial landscape by route of administration related to the mouth neoplasms market?
The mouth neoplasms market has been comprehensively analyzed in IMARC's new report titled "Mouth Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mouth neoplasms, also known as oral neoplasms or oral tumors, refer to abnormal growths or tumors that develop in the oral cavity. These tumors can occur in various structures within the mouth, including the tongue, lips, cheeks, gums, floor of the mouth, and roof of the mouth (palate). Some of the common symptoms are persistent mouth ulcers that do not heal, lumps or growths in the mouth, pain or discomfort in the throat, difficulty swallowing or chewing, bad breath, loose teeth or changes in dental alignment, unexplained bleeding or numbness in the mouth, etc. The diagnosis of mouth neoplasms involves a comprehensive evaluation by a healthcare professional specializing in oral health and oral pathology. The diagnostic process typically begins with a thorough medical history review and physical examination, including an analysis of the oral cavity and adjacent structures. Various imaging tests, such as X-rays, CT scans, MRI scans, etc., may be conducted to assess the extent and location of the neoplasm. Numerous additional procedures, including blood tests and molecular profiling, are also recommended to provide further information about the tumor's characteristics.
The increasing cases of tobacco use and alcohol consumption, which can damage the cells lining the oral cavity, thereby leading to the development of cancerous tumors, are primarily driving the mouth neoplasms market. In addition to this, the rising prevalence of various associated risk factors, including poor oral hygiene, nutritional deficiencies, excessive exposure to sunlight, inherited genetic syndromes, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of external beam radiation therapy on account of its several benefits, such as targeted treatment, combination therapy potential with surgery or chemotherapy, improved local control, pain management, etc., is further bolstering the market growth. Apart from this, the inflating application of transoral robotic surgery (TORS), since it avoids external incisions, thereby resulting in reduced trauma, minimal scarring, and potentially faster recovery times, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced imaging techniques, such as cone-beam computed tomography, which allows for real-time modifications to the radiation treatment plan, ensuring precise delivery of radiation to the tumor while minimizing exposure to healthy tissues, is expected to drive the mouth neoplasms market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the mouth neoplasms market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mouth neoplasms and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mouth neoplasms market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mouth neoplasms market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mouth neoplasms market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current mouth neoplasms marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the mouth neoplasms market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the mouth neoplasms market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the mouth neoplasms market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of mouth neoplasms across the seven major markets?
What is the number of prevalent cases (2018-2034) of mouth neoplasms by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of mouth neoplasms by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with mouth neoplasms across the seven major markets?
What is the size of the mouth neoplasms patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of mouth neoplasms?
What will be the growth rate of patients across the seven major markets?
Mouth Neoplasms: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for mouth neoplasms drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mouth neoplasms market?
What are the key regulatory events related to the mouth neoplasms market?
What is the structure of clinical trial landscape by status related to the mouth neoplasms market?
What is the structure of clinical trial landscape by phase related to the mouth neoplasms market?
What is the structure of clinical trial landscape by route of administration related to the mouth neoplasms market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MOUTH NEOPLASMS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MOUTH NEOPLASMS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MOUTH NEOPLASMS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MOUTH NEOPLASMS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MOUTH NEOPLASMS - UNMET NEEDS
10 MOUTH NEOPLASMS - KEY ENDPOINTS OF TREATMENT
11 MOUTH NEOPLASMS - MARKETED PRODUCTS
11.1 List of Mouth Neoplasms Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MOUTH NEOPLASMS - PIPELINE DRUGS
12.1 List of Mouth Neoplasms Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. MOUTH NEOPLASMS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MOUTH NEOPLASMS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MOUTH NEOPLASMS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Mouth Neoplasms - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Mouth Neoplasms - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Mouth Neoplasms - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Mouth Neoplasms - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Mouth Neoplasms - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Mouth Neoplasms - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Mouth Neoplasms - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Mouth Neoplasms - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Mouth Neoplasms - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Mouth Neoplasms - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Mouth Neoplasms - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Mouth Neoplasms - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Mouth Neoplasms - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Mouth Neoplasms - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Mouth Neoplasms - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Mouth Neoplasms - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Mouth Neoplasms - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Mouth Neoplasms - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Mouth Neoplasms - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Mouth Neoplasms - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Mouth Neoplasms - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Mouth Neoplasms - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Mouth Neoplasms - Access and Reimbursement Overview
16 MOUTH NEOPLASMS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MOUTH NEOPLASMS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MOUTH NEOPLASMS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MOUTH NEOPLASMS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MOUTH NEOPLASMS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MOUTH NEOPLASMS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MOUTH NEOPLASMS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MOUTH NEOPLASMS - UNMET NEEDS
10 MOUTH NEOPLASMS - KEY ENDPOINTS OF TREATMENT
11 MOUTH NEOPLASMS - MARKETED PRODUCTS
11.1 List of Mouth Neoplasms Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MOUTH NEOPLASMS - PIPELINE DRUGS
12.1 List of Mouth Neoplasms Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. MOUTH NEOPLASMS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MOUTH NEOPLASMS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MOUTH NEOPLASMS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Mouth Neoplasms - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Mouth Neoplasms - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Mouth Neoplasms - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Mouth Neoplasms - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Mouth Neoplasms - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Mouth Neoplasms - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Mouth Neoplasms - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Mouth Neoplasms - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Mouth Neoplasms - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Mouth Neoplasms - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Mouth Neoplasms - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Mouth Neoplasms - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Mouth Neoplasms - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Mouth Neoplasms - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Mouth Neoplasms - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Mouth Neoplasms - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Mouth Neoplasms - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Mouth Neoplasms - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Mouth Neoplasms - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Mouth Neoplasms - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Mouth Neoplasms - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Mouth Neoplasms - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Mouth Neoplasms - Access and Reimbursement Overview
16 MOUTH NEOPLASMS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MOUTH NEOPLASMS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MOUTH NEOPLASMS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
